Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.97 |
| ▸ | JAK1 | P23458 | 15/20 | 0.97 |
| ▸ | JAK2 | O60674 | 10/20 | 0.94 |
| ▸ | TYK2 | P29597 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534331 | 0.98 | JAK3 (1.00) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL3533457 | 0.97 | JAK3 (1.00) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL3542483 | 0.97 | JAK3 (1.00) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL3541754 | 0.97 | JAK3 (1.00) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL3535221 | 0.97 | JAK3 (1.00) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL3542178 | 0.97 | JAK3 (1.00) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL7088978 | 0.91 | JAK1 (0.81) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL22001726 | 0.90 | JAK1 (0.80) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL3532838 | 0.90 | JAK1 (1.00) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL29517918 | 0.90 | JAK1 (0.80) | JAK3JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180344-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE | PFIZER (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3290421-B1 | COMBINATION OF PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES WITH ONE OR MORE ADDITIONAL AGENTS AS INHIBITORS OF JANUS- RELATED KINASES (JAK) | PFIZER (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2958921-B1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS KINASES (JAK) | PFIZER (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9549929-B2 | Pyrrolo[2,3-D]pyrimidine derivatives | PFIZER INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| CN-1128800-C | Pyrolo [2,3-d] pyrimidine compounds | PFIZER PROD INC (US) | 2003-11-26 | — | — | CN | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| CN-1305480-A | Pyrrolo [2, 3-d ] pyrimidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885JAK2 3/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.